Gradient Investments LLC Has $1.62 Million Holdings in AstraZeneca plc (NYSE:AZN)

Gradient Investments LLC lessened its holdings in shares of AstraZeneca plc (NYSE:AZN) by 19.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,258 shares of the company’s stock after selling 8,534 shares during the period. Gradient Investments LLC’s holdings in AstraZeneca were worth $1,616,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in AZN. Buckingham Capital Management Inc. increased its position in shares of AstraZeneca by 113.2% during the 1st quarter. Buckingham Capital Management Inc. now owns 58,095 shares of the company’s stock valued at $2,349,000 after purchasing an additional 30,843 shares during the last quarter. Private Advisor Group LLC grew its position in AstraZeneca by 30.2% during the 1st quarter. Private Advisor Group LLC now owns 27,247 shares of the company’s stock worth $1,101,000 after acquiring an additional 6,321 shares during the last quarter. Commonwealth Equity Services LLC grew its position in AstraZeneca by 1.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 126,292 shares of the company’s stock worth $5,106,000 after acquiring an additional 2,011 shares during the last quarter. GYL Financial Synergies LLC bought a new position in AstraZeneca during the 1st quarter worth approximately $1,305,000. Finally, Primecap Management Co. CA grew its position in AstraZeneca by 0.3% during the 1st quarter. Primecap Management Co. CA now owns 56,343,156 shares of the company’s stock worth $2,277,954,000 after acquiring an additional 195,230 shares during the last quarter. Institutional investors own 17.52% of the company’s stock.

AstraZeneca stock opened at $44.02 on Friday. The firm has a market cap of $115.50 billion, a price-to-earnings ratio of 25.45, a PEG ratio of 1.47 and a beta of 0.47. The stock has a fifty day simple moving average of $44.34 and a two-hundred day simple moving average of $41.44. AstraZeneca plc has a 12 month low of $35.30 and a 12 month high of $46.22. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 1.19.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a return on equity of 35.83% and a net margin of 9.38%. The company had revenue of $5.72 billion during the quarter, compared to analyst estimates of $5.57 billion. During the same quarter in the previous year, the company posted $0.69 earnings per share. AstraZeneca’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that AstraZeneca plc will post 1.8 EPS for the current fiscal year.

In other news, major shareholder Plc Astrazeneca bought 425,000 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $8,075,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Several research firms recently issued reports on AZN. ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Argus raised their price target on AstraZeneca to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Zacks Investment Research lowered AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 3rd. Finally, DZ Bank lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company’s stock. AstraZeneca currently has an average rating of “Hold” and a consensus target price of $46.53.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: What are no-load funds?

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.